@entity1141 in @entity355 has been recognized to be morphologically heterogenous, featuring adenomatous, foveolar, and hybrid phenotypes. Recent studies have suggested a @entity5 suppressor role for @entity6628 in the @entity189 sequence. The phenotypic stability and role of @entity6628 in the @entity5 progression of different types of @entity1141 have not been evaluated. Thirty-eight endoscopic mucosal resections with @entity1141 and/or @entity189 ( @entity189 ) arising in @entity355 were evaluated for the expression of @entity5089 , @entity21826 , @entity5091 , @entity2282 , and @entity6628 . The background mucosa was also evaluated. The results were correlated with morphologic classification and clinicopathologic parameters. Of 38 endoscopic mucosal resections, 23 had @entity189 and @entity1141 , 8 had @entity189 only, and 7 had @entity1141 only. Among @entity75 , 73% were foveolar, 17% were adenomatous, and 10% were hybrid. Twenty of 23 cases with @entity1141 and adjacent @entity189 showed an identical immunophenotype of @entity1141 and @entity189 comprising 16 gastric, 3 intestinal, and 1 mixed immunophenotype. Three cases showed discordance of @entity1141 and @entity189 immunophenotype. These findings suggest that most Barrett-related @entity189 cases are either gastric or intestinal, with phenotypic stability during progression supporting separate gastric and intestinal pathways of @entity105 . @entity6628 showed gradual downregulation of expression during progression in @entity1412 but not in foveolar or hybrid @entity1141 , supporting a @entity5 suppressor role, at least in the intestinal pathway. @entity6628 was also found to be expressed to a greater degree in @entity1944 compared with nonintestinalized columnar metaplasia. Consistent with @entity6628 as a @entity5 suppressor, this suggests that nonintestinalized columnar metaplasia may be an unstable intermediate state at risk for @entity5 progression.

Divergent expression of @entity5089 , XXXX , @entity5091 , @entity2282 , and @entity6628 in @entity1141 and intramucosal adenocarcinomas with intestinal and foveolar morphology: is this evidence of distinct gastric and intestinal pathways to @entity105 in @entity355 ?

@entity6628 :: ('1045', 'Gene') :: ['CDX-2'] @entity1944 :: ('MESH:D007410', 'Disease') :: ['intestinal metaplasia'] @entity355 :: ('MESH:D001471', 'Disease') :: ['Barrett esophagus'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'neoplastic'] @entity75 :: ('MESH:D001927', 'Disease') :: ['dysplastic lesions'] @entity5091 :: ('4583', 'Gene') :: ['MUC2'] @entity1412 :: ('MESH:D011125', 'Disease') :: ['adenomatous dysplasia'] @entity189 :: ('MESH:D002277', 'Disease') :: ['intramucosal carcinoma', 'IMC', 'metaplasia-dysplasia-carcinoma'] @entity2282 :: ('4311', 'Gene') :: ['CD10'] @entity5089 :: ('4586', 'Gene') :: ['MUC5AC'] @entity21826 :: ('4588', 'Gene') :: ['MUC6'] @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis'] @entity1141 :: ('MESH:C535662', 'Disease') :: ['dysplasia', 'Dysplasia', 'dysplasias']
@entity21826 :: (4588,Gene) :: ['MUC6']
